New York, New York — September 2, 2025 — Leads & Copy — OS Therapies Inc. (NYSE American: OSTX) has completed a warrant inducement and exchange offer, raising $3.7 million in gross proceeds to advance commercial preparations for OST-HER2.
The funds will accelerate the potential commercialization of OST-HER2 in the prevention of recurrent pulmonary metastatic osteosarcoma, pending FDA approval. The company has funding into 2027.
The warrant exchange involved holders of outstanding warrants with a $1.12 per share exercise price. New warrants issued have a $3.00 per share exercise price with a forced exercise provision when the stock trades above $9.00.
According to Paul Romness, MPH, Chairman & CEO of OS Therapies, the company expects over $20 million in additional funding would flow into the Company, allowing them to resume the clinical development of OST-504 in prostate cancer, as well as drive additional value-building activities in their OS Animal Health and OS Drug Conjugates subsidiaries. Ceros Financial Services, Inc. acted as the exclusive warrant solicitation agent for the transaction.
OS Therapies is focused on developing treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2 has received FDA Rare Pediatric Disease Designation and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency.
Investor Relations Contact: Harrison Seidner, PhD, WaterSeid Partners, OSTX@waterseid.com
Public Relations Contact: Stephanie Chen, Elev8 New Media, stephanie@elev8newmedia.com
Source: OS Therapies Inc.
